Literature DB >> 19128199

Role of the dopamine transporter in the action of psychostimulants, nicotine, and other drugs of abuse.

J Zhu1, M E A Reith.   

Abstract

A number of studies over the last two decades have demonstrated the critical importance of dopamine (DA) in the behavioral pharmacology and addictive properties of abused drugs. The DA transporter (DAT) is a major target for drugs of abuse in the category of psychostimulants, and for methylphenidate (MPH), a drug used for treating attention deficit hyperactivity disorder (ADHD), which can also be a psychostimulant drug of abuse. Other drugs of abuse such as nicotine, ethanol, heroin and morphine interact with the DAT in more indirect ways. Despite the different ways in which drugs of abuse can affect DAT function, one evolving theme in all cases is regulation of the DAT at the level of surface expression. DAT function is dynamically regulated by multiple intracellular and extracellular signaling pathways and several protein-protein interactions. In addition, DAT expression is regulated through the removal (internalization) and recycling of the protein from the cell surface. Furthermore, recent studies have demonstrated that individual differences in response to novel environments and psychostimulants can be predicted based on individual basal functional DAT expression. Although current knowledge of multiple factors regulating DAT activity has greatly expanded, many aspects of this regulation remain to be elucidated; these data will enable efforts to identify drugs that might be used therapeutically for drug dependence therapeutics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19128199      PMCID: PMC3133725          DOI: 10.2174/187152708786927877

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  291 in total

Review 1.  New insights into the mechanism of action of amphetamines.

Authors:  Annette E Fleckenstein; Trent J Volz; Evan L Riddle; James W Gibb; Glen R Hanson
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

2.  Regulation of dopamine transporter function and cell surface expression by D3 dopamine receptors.

Authors:  Agustin Zapata; Bronwyn Kivell; Yang Han; Jonathan A Javitch; Elizabeth A Bolan; David Kuraguntla; Vanaja Jaligam; Murat Oz; Lankupalle D Jayanthi; Devadoss J Samuvel; Sammanda Ramamoorthy; Toni S Shippenberg
Journal:  J Biol Chem       Date:  2007-10-08       Impact factor: 5.157

3.  Dopamine transporter ligand binding domains. Structural and functional properties revealed by limited proteolysis.

Authors:  R A Vaughan; M J Kuhar
Journal:  J Biol Chem       Date:  1996-08-30       Impact factor: 5.157

Review 4.  Molecular mechanisms of drug reinforcement and addiction.

Authors:  D W Self; E J Nestler
Journal:  Annu Rev Neurosci       Date:  1995       Impact factor: 12.449

5.  Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain.

Authors:  N D Volkow; G J Wang; J S Fowler; M Fischman; R Foltin; N N Abumrad; S J Gatley; J Logan; C Wong; A Gifford; Y S Ding; R Hitzemann; N Pappas
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

6.  Alcohol consumption alters dopamine transporter sites in Wistar-Kyoto rat brain.

Authors:  X Jiao; W P Paré; S M Tejani-Butt
Journal:  Brain Res       Date:  2006-02-02       Impact factor: 3.252

7.  Cocaine use increases [3H]WIN 35428 binding sites in human striatum.

Authors:  K Y Little; J A Kirkman; F I Carroll; T B Clark; G E Duncan
Journal:  Brain Res       Date:  1993-11-19       Impact factor: 3.252

Review 8.  Rapid regulation of the dopamine transporter: role in stimulant addiction?

Authors:  Nancy R Zahniser; Alexander Sorkin
Journal:  Neuropharmacology       Date:  2004       Impact factor: 5.250

9.  2-Carbomethoxy-3-(diarylmethoxy)-1 alpha H, 5 alpha H-tropane analogs: synthesis and inhibition of binding at the dopamine transporter and comparison with piperazines of the GBR series.

Authors:  P C Meltzer; A Y Liang; B K Madras
Journal:  J Med Chem       Date:  1996-01-19       Impact factor: 7.446

Review 10.  Probes for the dopamine transporter: new leads toward a cocaine-abuse therapeutic--A focus on analogues of benztropine and rimcazole.

Authors:  Amy Hauck Newman; Santosh Kulkarni
Journal:  Med Res Rev       Date:  2002-09       Impact factor: 12.944

View more
  49 in total

Review 1.  The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder.

Authors:  Amy F T Arnsten
Journal:  Expert Rev Neurother       Date:  2010-10       Impact factor: 4.618

2.  Dual role of PPAR-γ in induction and expression of behavioral sensitization to cannabinoid receptor agonist WIN55,212-2.

Authors:  Leili Enayatfard; Farzaneh Rostami; Sanaz Nasoohi; Shahrbanoo Oryan; Abolhassan Ahmadiani; Leila Dargahi
Journal:  Neuromolecular Med       Date:  2013-06-21       Impact factor: 3.843

3.  Fenproporex increases locomotor activity and alters energy metabolism, and mood stabilizers reverse these changes: a proposal for a new animal model of mania.

Authors:  Gislaine T Rezin; Camila B Furlanetto; Giselli Scaini; Samira S Valvassori; Cinara L Gonçalves; Gabriela K Ferreira; Isabela C Jeremias; Wilson R Resende; Mariane R Cardoso; Roger B Varela; João Quevedo; Emilio L Streck
Journal:  Mol Neurobiol       Date:  2013-10-15       Impact factor: 5.590

4.  Knockout of latrophilin-3 in Sprague-Dawley rats causes hyperactivity, hyper-reactivity, under-response to amphetamine, and disrupted dopamine markers.

Authors:  Samantha L Regan; Jillian R Hufgard; Emily M Pitzer; Chiho Sugimoto; Yueh-Chiang Hu; Michael T Williams; Charles V Vorhees
Journal:  Neurobiol Dis       Date:  2019-06-06       Impact factor: 5.996

5.  Computational modeling of human dopamine transporter structures, mechanism and its interaction with HIV-1 transactivator of transcription.

Authors:  Yaxia Yuan; Xiaoqin Huang; Jun Zhu; Chang-Guo Zhan
Journal:  Future Med Chem       Date:  2016-10-14       Impact factor: 3.808

Review 6.  Examining the complex regulation and drug-induced plasticity of dopamine release and uptake using voltammetry in brain slices.

Authors:  Mark J Ferris; Erin S Calipari; Jordan T Yorgason; Sara R Jones
Journal:  ACS Chem Neurosci       Date:  2013-05-06       Impact factor: 4.418

Review 7.  The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities.

Authors:  Stephen V Faraone
Journal:  Neurosci Biobehav Rev       Date:  2018-02-08       Impact factor: 8.989

8.  [3H]Dopamine Uptake through the Dopamine and Norepinephrine Transporters is Decreased in the Prefrontal Cortex of Transgenic Mice Expressing HIV-1 Transactivator of Transcription Protein.

Authors:  Matthew Strauss; Bernadette O'Donovan; Yizhi Ma; Ziyu Xiao; Steven Lin; Michael T Bardo; Pavel I Ortinski; Jay P McLaughlin; Jun Zhu
Journal:  J Pharmacol Exp Ther       Date:  2020-05-27       Impact factor: 4.030

9.  Melatonin inhibits manganese-induced motor dysfunction and neuronal loss in mice: involvement of oxidative stress and dopaminergic neurodegeneration.

Authors:  Yu Deng; Congcong Jiao; Chao Mi; Bin Xu; Yuehui Li; Fei Wang; Wei Liu; Zhaofa Xu
Journal:  Mol Neurobiol       Date:  2014-06-28       Impact factor: 5.590

10.  Intracellular methamphetamine prevents the dopamine-induced enhancement of neuronal firing.

Authors:  Kaustuv Saha; Danielle Sambo; Ben D Richardson; Landon M Lin; Brittany Butler; Laura Villarroel; Habibeh Khoshbouei
Journal:  J Biol Chem       Date:  2014-06-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.